- +1-315-215-1633
- sales@thebrainyinsights.com
The global Parkinson’s disease treatment market is expected to grow from USD 5.87 billion in 2022 to USD 12.15 billion by 2032, at a CAGR of 7.55% during the forecast period 2023-2032. The North American region dominated the market in 2022.
Parkinson's disease is a brain disorder that results in uncontrollable movements like stiffness, trembling, and issues with coordination and blood. Usually, symptoms are minor to begin with, and worsen over time. As the condition develops, individuals may have trouble speaking and moving about. Additionally, the patient may experience behavioral changes, depression, sleep issues, and memory loss. The risk of acquiring Parkinson's is almost at anyone; however, certain studies indicate that men are more vulnerable to this condition. The basal ganglia experience nerve cell death and impairment, which is one of the most prevalent symptoms of Parkinson's disease. Norepinephrine, the primary chemical messenger of the sympathetic nervous system that controls several essential functions like heart rate and blood pressure, is majorly impacted by Parkinson's disease. There are numerous medicinal and surgical options for treating Parkinson's disease.
Get an overview of this study by requesting a free sample
Increasing prevalence of Parkinson’s disease treatment: Many people around the globe have developed Parkinson's disease in the last two decades compared to other neurological disorders. According to recent estimates, Parkinson’s disease caused 329,000 deaths in 2019, an increase of over a hundred percent in two decades. Aging is one of the common factors contributing to the rising prevalence of Parkinson’s disease. Numerous studies have demonstrated that environmental elements such as pesticides, industrial solvents, and air pollution may raise the risk of developing Parkinson's disease. In the United States, almost a million people have Parkinson's disease. By 2030, it is anticipated that this number will reach 1.2 million. After Alzheimer's disease, Parkinson's disease is the most common neurodegenerative condition.
Potential side effects– Drugs for Parkinson's disease tend to be safe usually. However, there are a few possible side effects. Additionally, some of these medications may interfere with other prescription drugs that the patients consume. Only 57% of younger patients prefer using drugs. This is probably because the adverse effects of the treatments are sometimes worse than the disease's symptoms.
Growing healthcare investments- The increase in government investment in pharmaceutical research and development in emerging countries can be attributed to numerous factors such as rising healthcare expenditure, progressing clinical diagnostics and drug discovery fields, emerging applications, technological advancements, growing geriatric populations, and changing demographics. Several industry participants have invested considerable funds in their pipeline projects. Further, the increasing healthcare investments are primarily driven by robust healthcare growth in developed and developing countries such as the US, UK, Germany, China, Japan, and India. Advances have aided the growth of the Parkinson’s disease treatment market in drug development innovations. As a result, high-end treatment procedures are being developed, further fueling the Parkinson’s disease treatment market.
Stringent regulations for drug approval - The concerned regional agencies' approval is required so Parkinson's disease treatment can be used on patients. These drugs are used in critical treatment procedures for Parkinson’s disease. Thus, manufacturers must receive product approvals from different agencies to sell their products in each region.
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. The North American region emerged as the most significant global Parkinson’s disease treatment market, with a revenue share of 36.08% in 2022. The region has a high market growth rate due to an increasing prevalence of Parkinson’s disease. The North American market will be driven by investment in the healthcare sector to support the Parkinson’s disease treatment market. The growing investment by regional agencies and support of research and development policies provide lucrative growth opportunities to the market. The Asia-Pacific region is anticipated to grow lucratively during the forecast period. The market is witnessing a lucrative growth rate due to the rising geriatric population in countries like Japan and China. Further, the increasing awareness among the patient population will propel market growth.
North America Region Parkinson’s Disease Treatment Market Share in 2022 - 36.08%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
The drug class segment is divided into dopamine agonists, COMT inhibitors, MAO-B inhibitors, anticholinergics, carbidopa-levodopa, and others. The carbidopa-levodopa segment dominated the market with a revenue share of 29.20% in 2022. Levodopa and carbidopa are among the most effective drug combinations to treat Parkinson's disease. It is found to be the most potent and is widely used as a second line of treatment.
The administration route segment includes injection, oral and transdermal. The oral segment dominated the market with a revenue share of 47.10% in 2022. Oral administration is the most convenient administration route for most patients. Thus, the demand for oral administration is high among the geriatric population.
The distribution channel segment includes retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies segment dominated the market with a revenue share of 45.55% in 2022. Retail pharmacies provide all the medications used for managing the symptoms of Parkinson's disease. Also, retail pharmacies are more accessible as compared to other pharmacies.
The patient care facility segment includes hospitals and clinics. The hospital segment dominated the market with a revenue share of 79.21% in 2022. Patients with Parkinson's disease usually prefer to visit hospitals for treatment procedures. Hospitals have far more treatment options available in comparison to local clinics.
Report Description:
| Attribute | Description |
|---|---|
| Market Size | Revenue (USD Billion) |
| Market size value in 2022 | USD 5.87 Billion |
| Market size value in 2032 | USD 12.15 Billion |
| CAGR (2022 to 2032) | 7.55% |
| Historical data | 2019-2021 |
| Base Year | 2022 |
| Forecast | 2023-2032 |
| Regional Segments | The regions examined for the market are Europe, Asia Pacific, North America, South America, and Middle East & Africa. |
| Segments | The research segment is based on drug class, administration route, distribution channel, and patient care facility. |
As per The Brainy Insights, the size of the Parkinson’s disease treatment market was valued 5.87 billion in 2022 to USD 12.15 billion by 2032.
Global Parkinson’s disease treatment market is growing at a CAGR of 7.55% during the forecast period 2023-2032.
North America region emerged as the largest market for the Parkinson’s disease treatment.
The market's growth will be influenced by the growing prevalence of Parkinson’s disease.
The potential side-effects of Parkinson’s disease treatment could hamper the market growth.
The increasing investment in research and development for drug development is providing huge opportunities to the market.
1. Introduction
1.1. Objective of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis By Drug Class
4.3.2. Market Attractiveness Analysis By Administration Route
4.3.3. Market Attractiveness Analysis By Distribution Channel
4.3.4. Market Attractiveness Analysis By Patient Care Facility
4.3.5. Market Attractiveness Analysis By Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. Increasing prevalence of Parkinson’s disease
5.3. Restraints
5.3.1. Potential side effects
5.4. Opportunities
5.4.1. Increasing investments in research and development in drug development
5.5. Challenges
5.5.1. Stringent clinical regulations
6. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Drug Class
6.1. Segment Overview
6.2. Dopamine Agonists
6.3. COMT Inhibitors
6.4. MAO-B Inhibitors
6.5. Anticholinergics
6.6. Carbidopa-Levodopa
6.7. Others
7. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Administration Route
7.1. Segment Overview
7.2. Injection
7.3. Oral
7.4. Transdermal
8. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Distribution Channel
8.1. Segment Overview
8.2. Retail Pharmacies
8.3. Hospital Pharmacies
8.4. Online Pharmacies
9. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Patient Care Facility
9.1. Segment Overview
9.2. Hospitals
9.3. Clinics
10. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Regional Analysis
10.1. Segment Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.5. South America
10.5.1. Brazil
10.6. Middle East and Africa
10.6.1. UAE
10.6.2. South Africa
11. Global Parkinson’s Disease Treatment Market-Competitive Landscape
11.1. Overview
11.2. Market Share of Key Players in the Parkinson’s Disease Treatment Market
11.2.1. Global Company Market Share
11.2.2. North America Company Market Share
11.2.3. Europe Company Market Share
11.2.4. APAC Company Market Share
11.3. Competitive Situations and Trends
11.3.1. Product Launches and Developments
11.3.2. Partnerships, Collaborations, and Agreements
11.3.3. Mergers & Acquisitions
11.3.4. Expansions
12. Company Profiles
12.1. Cerevel Therapeutics
12.1.1. Business Overview
12.1.2. Company Snapshot
12.1.3. Company Market Share Analysis
12.1.4. Company Product Portfolio
12.1.5. Recent Developments
12.1.6. SWOT Analysis
12.2. Teva Pharmaceutical Industries Ltd.
12.2.1. Business Overview
12.2.2. Company Snapshot
12.2.3. Company Market Share Analysis
12.2.4. Company Product Portfolio
12.2.5. Recent Developments
12.2.6. SWOT Analysis
12.3. Novartis AG
12.3.1. Business Overview
12.3.2. Company Snapshot
12.3.3. Company Market Share Analysis
12.3.4. Company Product Portfolio
12.3.5. Recent Developments
12.3.6. SWOT Analysis
12.4. Merck & Co., Inc.
12.4.1. Business Overview
12.4.2. Company Snapshot
12.4.3. Company Market Share Analysis
12.4.4. Company Product Portfolio
12.4.5. Recent Developments
12.4.6. SWOT Analysis
12.5. AbbVie, Inc.
1.1.1. Business Overview
1.1.2. Company Snapshot
1.1.3. Company Market Share Analysis
1.1.4. Company Product Portfolio
1.1.5. Recent Developments
1.1.6. SWOT Analysis
12.6. GlaxoSmithKline plc.
12.6.1. Business Overview
12.6.2. Company Snapshot
12.6.3. Company Market Share Analysis
12.6.4. Company Product Portfolio
12.6.5. Recent Developments
12.6.6. SWOT Analysis
12.7. Boehringer Ingelheim International GmbH
12.7.1. Business Overview
12.7.2. Company Snapshot
12.7.3. Company Market Share Analysis
12.7.4. Company Product Portfolio
12.7.5. Recent Developments
12.7.6. SWOT Analysis
12.8. H. Lundbeck A/S
12.8.1. Business Overview
12.8.2. Company Snapshot
12.8.3. Company Market Share Analysis
12.8.4. Company Product Portfolio
12.8.5. Recent Developments
12.8.6. SWOT Analysis
12.9. Supernus Pharmaceuticals, Inc
12.9.1. Business Overview
12.9.2. Company Snapshot
12.9.3. Company Market Share Analysis
12.9.4. Company Product Portfolio
12.9.5. Recent Developments
12.9.6. SWOT Analysis
12.10. Amneal Pharmaceuticals LLC
12.10.1. Business Overview
12.10.2. Company Snapshot
12.10.3. Company Market Share Analysis
12.10.4. Company Product Portfolio
12.10.5. Recent Developments
12.10.6. SWOT Analysis
12.11. Zydus Cadila
12.11.1. Business Overview
12.11.2. Company Snapshot
12.11.3. Company Market Share Analysis
12.11.4. Company Product Portfolio
12.11.5. Recent Developments
12.11.6. SWOT Analysis
12.12. Sun Pharmaceutical Industries Ltd.
12.12.1. Business Overview
12.12.2. Company Snapshot
12.12.3. Company Market Share Analysis
12.12.4. Company Product Portfolio
12.12.5. Recent Developments
12.12.6. SWOT Analysis
12.13. Dr. Reddy’s Laboratories
12.13.1. Business Overview
12.13.2. Company Snapshot
12.13.3. Company Market Share Analysis
12.13.4. Company Product Portfolio
12.13.5. Recent Developments
12.13.6. SWOT Analysis
12.14. Cipla Inc.
12.14.1. Business Overview
12.14.2. Company Snapshot
12.14.3. Company Market Share Analysis
12.14.4. Company Product Portfolio
12.14.5. Recent Developments
12.14.6. SWOT Analysis
List of Table
1. Global Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
2. Global Dopamine Agonists, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
3. Global COMT Inhibitors, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
4. Global MAO-B Inhibitors, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
5. Global Anticholinergics, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
6. Global Carbidopa-Levodopa, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
7. Global Others, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
8. Global Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
9. Global Injection, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
10. Global Oral, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
11. Global Transdermal, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
12. Global Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
13. Global Retail Pharmacies, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
14. Global Hospital Pharmacies, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
15. Global Online Pharmacies, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
16. Global Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
17. Global Hospitals, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
18. Global Clinics, Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
19. Global Parkinson’s Disease Treatment Market, By Region, 2019-2032 (USD Billion)
20. North America Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
21. North America Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
22. North America Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
23. North America Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
24. U.S. Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
25. U.S. Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
26. U.S. Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
27. U.S. Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
28. Canada Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
29. Canada Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
30. Canada Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
31. Canada Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
32. Mexico Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
33. Mexico Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
34. Mexico Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
35. Mexico Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
36. Europe Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
37. Europe Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
38. Europe Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
39. Europe Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
40. Germany Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
41. Germany Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
42. Germany Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
43. Germany Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
44. France Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
45. France Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
46. France Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
47. France Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
48. U.K. Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
49. U.K. Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
50. U.K. Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
51. U.K. Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
52. Italy Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
53. Italy Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
54. Italy Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
55. Italy Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
56. Spain Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
57. Spain Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
58. Spain Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
59. Spain Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
60. Asia Pacific Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
61. Asia Pacific Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
62. Asia Pacific Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
63. Asia Pacific Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
64. Japan Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
65. Japan Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
66. Japan Parkinson’s Disease Treatment Market, By Distribution Channel 2019-2032 (USD Billion)
67. Japan Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
68. China Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
69. China Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
70. China Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
71. China Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
72. India Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
73. India Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
74. India Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
75. India Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
76. South America Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
77. South America Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
78. South America Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
79. South America Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
80. Brazil Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
81. Brazil Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
82. Brazil Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
83. Brazil Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
84. Middle East and Africa Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
85. Middle East and Africa Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
86. Middle East and Africa Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
87. Middle East and Africa Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
88. UAE Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
89. UAE Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
90. UAE Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
91. UAE Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
92. South Africa Parkinson’s Disease Treatment Market, By Drug Class, 2019-2032 (USD Billion)
93. South Africa Parkinson’s Disease Treatment Market, By Administration Route, 2019-2032 (USD Billion)
94. South Africa Parkinson’s Disease Treatment Market, By Distribution Channel, 2019-2032 (USD Billion)
95. South Africa Parkinson’s Disease Treatment Market, By Patient Care Facility, 2019-2032 (USD Billion)
List of Figures
1. Global Parkinson’s Disease Treatment Market Segmentation
2. Parkinson’s Disease Treatment Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Parkinson’s Disease Treatment Market Attractiveness Analysis By Drug Class
9. Global Parkinson’s Disease Treatment Market Attractiveness Analysis By Administration Route
10. Global Parkinson’s Disease Treatment Market Attractiveness Analysis By Distribution Channel
11. Global Parkinson’s Disease Treatment Market Attractiveness Analysis By Patient Care Facility
12. Global Parkinson’s Disease Treatment Market Attractiveness Analysis By Region
13. Global Parkinson’s Disease Treatment Market: Dynamics
14. Global Parkinson’s Disease Treatment Market Share by Drug Class (2022 & 2032)
15. Global Parkinson’s Disease Treatment Market Share by Administration Route (2022 & 2032)
16. Global Parkinson’s Disease Treatment Market Share by Distribution Channel (2022 & 2032)
17. Global Parkinson’s Disease Treatment Market Share by Patient Care Facility (2022 & 2032)
18. Global Parkinson’s Disease Treatment Market Share by Regions (2022 & 2032)
19. Global Parkinson’s Disease Treatment Market Share by Company (2022)
This study forecasts revenue at global, regional, and country levels from 2019 to 2032. The Brainy Insights has segmented the global Parkinson’s disease treatment market based on below mentioned segments:
Global Parkinson’s Disease Treatment Market by Drug Class:
Global Parkinson’s Disease Treatment Market by Administration Route:
Global Parkinson’s Disease Treatment Market by Distribution Channel:
Global Parkinson’s Disease Treatment Market by Patient Care Facility:
Global Parkinson’s Disease Treatment Market by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date
